Guangzhou Dabio Biologics Receives CDE IND Acceptance for Umbilical Cord Mesenchymal Stem Cell Injection (E10I) Targeting Type 2 Diabetes

Nov 16, 2023 17:00 CST Updated 17:01

Double Bioproduct

Developer of Anti-Tumor Gene Therapy Drugs

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

NEWS

Guangzhou Dabo Biological Products Co., Ltd. (referred to as "Dabo Bio") recentlyIssued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA)RegardingHuman Umbilical Cord Mesenchymal Stem Cell InjectionThe acceptance notice for the Phase I clinical trial application, with the acceptance number beingCXSL2300769。

Human Umbilical Cord Mesenchymal Stem Cell Injection（E10I）Is byDabo BioThe independently developed cryopreservation-type stem cell preparation is a suspension of human umbilical cord mesenchymal stem cells obtained from umbilical cord tissue through in vitro separation, screening, and large-scale three-dimensional expansion. It is clinically intended for the treatment of type 2 diabetes.

About E10I

……

Human umbilical cord mesenchymal stem cells (hUC-MSCs) are a type of mesenchymal stem cell present in Wharton’s jelly and the perivascular tissue of the umbilical cord. Mesenchymal stem cells derived from the umbilical cord are ideal for clinical research and applications due to their convenient sourcing, absence of ethical controversies, high yield of cells, strong proliferation ability, significant immunomodulatory effects, and substantial secretion of growth factors. They are also easy to expand and passage, with no issues related to matching or rejection.

Guangzhou Dabo Biological Products Co., Ltd. has rich experience in the isolation, purification, amplification, and clinical application of stem cells, and has currently launchedUmbilical Cord Mesenchymal Stem Cells（E10I）Clinical research on the treatment of diabetes and rheumatoid arthritis.

About Dabo Bio

Guangzhou Dabo Biological Products Co., Ltd. is committed to independent research and development, clinical research, and commercial production. The companyA series of product lines with independent intellectual property rights have been developed, and multiple clinical trial approvals have been obtained. Projects are currently in various stages such as Phase I, Phase II, and Phase III clinical trials. Among them, E10A (Recombinant Human Endostatin Adenovirus Injection) is China's first gene therapy drug to enter Phase III clinical trials, and E10H (Autologous NK Cell Injection) is China’s first approved NK cell therapy drug to enter clinical trials.

Source of the article:

Dabo Bio